Skip to main content

Predictive Biosciences Raises $21.75M in Private Financing

NEW YORK (GenomeWeb News) – Predictive Biosciences has closed a Series B financing that has brought in $21.75 million in funding, the Lexington, Mass.-based company said today.
 
Predictive Bio is developing biomarker-based assays for a variety of cancers, with an initial focus on bladder cancer. The firm also is looking into developing tests for breast, ovarian, prostate, and colorectal cancers.
 
Predictive Bio said the funds would be used to complete current clinical validation studies and initiate multi-center clinical trials. It also said proceeds would fund efforts to open a CLIA-compliant lab to run diagnostic tests.
 
The financing round was led by New Enterprise Associates and included Kaiser Permanente Ventures, as well investors from its $10 million Series A round including Flybridge Capital Partners and Highland Capital Partners.
 
In conjunction with the most recent financing, NEA General Partner James Barrett has joined Predictive Bio’s board of directors, and Kaiser Permanente Ventures Senior Venture Manager Jordan Kramer has been named a board observer.

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.